184 related articles for article (PubMed ID: 35801839)
1. COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era.
Hedvat J; Lange NW; Salerno DM; DeFilippis EM; Kovac D; Corbo H; Chen JK; Choe JY; Lee JH; Anamisis A; Jennings DL; Codispodo G; Shertel T; Brown RS; Pereira MR
Am J Transplant; 2022 Nov; 22(11):2682-2688. PubMed ID: 35801839
[TBL] [Abstract][Full Text] [Related]
2. Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge.
Radcliffe C; Palacios CF; Azar MM; Cohen E; Malinis M
Am J Transplant; 2022 Oct; 22(10):2458-2463. PubMed ID: 35583664
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.
Yetmar ZA; Beam E; O'Horo JC; Seville MT; Brumble L; Ganesh R; Razonable RR
Transpl Infect Dis; 2022 Aug; 24(4):e13901. PubMed ID: 35848574
[TBL] [Abstract][Full Text] [Related]
5. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients.
Salerno DM; Jennings DL; Lange NW; Kovac DB; Shertel T; Chen JK; Hedvat J; Scheffert J; Brown RS; Pereira MR
Am J Transplant; 2022 Aug; 22(8):2083-2088. PubMed ID: 35278260
[TBL] [Abstract][Full Text] [Related]
6. Sotrovimab therapy in solid organ transplant recipients with mild to moderate COVID-19: a systematic review and meta-analysis.
Farhadian N; Farhadian M; Zamanian MH; Taghadosi M; Vaziri S
Immunopharmacol Immunotoxicol; 2023 Dec; 45(4):402-408. PubMed ID: 36537311
[No Abstract] [Full Text] [Related]
7. A single-center review of pre-exposure prophylaxis with tixagevimab-cilgavimab in solid organ transplant recipients.
Morado F; Davoudi R; Kawewat-Ho P; Nanda N; Cartus R; Shaikh SA
Transpl Infect Dis; 2023 Aug; 25(4):e14086. PubMed ID: 37314092
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of severe acute respiratory syndrome coronavirus 2 monoclonal antibodies in high-risk solid organ transplant recipients across three major coronavirus disease 2019 variant waves.
Zeitler K; Piccicacco N; O'Neal M; Montero J; Myers A; Strebig D; Nestler S; Anger LB; Kim K
Transpl Infect Dis; 2023 Aug; 25(4):e14095. PubMed ID: 37378536
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 Infection With the Omicron SARS-CoV-2 Variant in a Cohort of Kidney and Kidney Pancreas Transplant Recipients: Clinical Features, Risk Factors, and Outcomes.
Wong G; Rowlandson M; Sabanayagam D; Ginn AN; Kable K; Sciberras F; Au E; Draper J; Arnott A; Sintchenko V; Dwyer DE; Chen SCA; Kok J
Transplantation; 2022 Sep; 106(9):1860-1866. PubMed ID: 35675438
[TBL] [Abstract][Full Text] [Related]
10. Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir.
Martin-Blondel G; Marcelin AG; Soulié C; Kaisaridi S; Lusivika-Nzinga C; Zafilaza K; Dorival C; Nailler L; Boston A; Ronchetti AM; Melenotte C; Cabié A; Choquet C; Trinh-Duc A; Lacombe K; Gaube G; Coustillères F; Pourcher V; Martellosio JP; Peiffer-Smadja N; Chauveau M; Housset P; Piroth L; Devaux M; Pialoux G; Martin A; Dubee V; Frey J; Le Bot A; Cazanave C; Petua P; Liblau R; Carrat F; Yordanov Y
Clin Microbiol Infect; 2023 Apr; 29(4):543.e5-543.e9. PubMed ID: 36586513
[TBL] [Abstract][Full Text] [Related]
11. Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients.
Yetmar ZA; Bhaimia E; Razonable RR
Curr Opin Organ Transplant; 2022 Aug; 27(4):269-276. PubMed ID: 36354253
[TBL] [Abstract][Full Text] [Related]
12. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase.
Aggarwal NR; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Molina KC; Peers JL; Russell S; Wynia MK; Ginde AA
Int J Infect Dis; 2023 Mar; 128():310-317. PubMed ID: 36229005
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients With SARS-CoV-2 During the Omicron Predominant Era.
Al-Obaidi MM; Gungor AB; Murugapandian S; Thajudeen B; Mansour I; Wong RC; Tanriover B; Zangeneh TT
Am J Med; 2023 Jun; 136(6):577-584. PubMed ID: 36898600
[TBL] [Abstract][Full Text] [Related]
14. Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge.
Avery RK
Transplantation; 2022 Aug; 106(8):1528-1537. PubMed ID: 35700481
[TBL] [Abstract][Full Text] [Related]
15. Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave.
Solera JT; Árbol BG; Bahinskaya I; Marks N; Humar A; Kumar D
Am J Transplant; 2023 Jan; 23(1):78-83. PubMed ID: 36148607
[TBL] [Abstract][Full Text] [Related]
16. Is the Omicron variant truly less virulent in solid organ transplant recipients?
Anjan S; Khatri A; Viotti JB; Cheung T; Garcia LAC; Simkins J; Loebe M; Phancao A; O'Brien CB; Sinha N; Ciancio G; Vianna RM; Andrews D; Abbo LM; Guerra G; Natori Y
Transpl Infect Dis; 2022 Dec; 24(6):e13923. PubMed ID: 35915957
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of COVID-19 in solid organ transplant recipients following COVID-19 vaccination: A multicenter case series.
Saharia KK; Anjan S; Streit J; Beekmann SE; Polgreen PM; Kuehnert M; Segev DL; Baddley JW; Miller RA;
Transpl Infect Dis; 2022 Apr; 24(2):e13774. PubMed ID: 34905269
[TBL] [Abstract][Full Text] [Related]
18. Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 Outcomes in Organ Transplant Recipients During the Omicron Wave.
Solera JT; Árbol BG; Alshahrani A; Bahinskaya I; Marks N; Humar A; Kumar D
Clin Infect Dis; 2022 Dec; 75(12):2193-2200. PubMed ID: 35445690
[TBL] [Abstract][Full Text] [Related]
19. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.
Al Jurdi A; Morena L; Cote M; Bethea E; Azzi J; Riella LV
Am J Transplant; 2022 Dec; 22(12):3130-3136. PubMed ID: 35727916
[TBL] [Abstract][Full Text] [Related]
20. Assessing the post hoc effectiveness of tixagevimab-cilgavimab for prevention of SARS-CoV-2 infections in solid organ transplant recipients.
Jordan SC; Joung SY; Wang M; Tran TA; Bravo M; Masoom H; Chang C; Mendez M; Sun N; Patel J; Kittleson M; Frias E; Prostko JC; Ebinger JE; Cheng S; Sobhani K
Transpl Infect Dis; 2024 Feb; 26(1):e14182. PubMed ID: 37885435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
